| 尹振宇,刘 乾,李晓梅.胃癌靶向治疗药物及耐药机制的研究进展[J].中国肿瘤,2021,30(9):701-710. |
| 胃癌靶向治疗药物及耐药机制的研究进展 |
| Progress on Targeted Therapy and Drug Resistance Mechanism of Gastric Cancer |
| 中文关键词 修订日期：2021-01-30 |
| DOI：10.11735/j.issn.1004-0242.2021.09.A011 |
|
 |
| 中文关键词: 胃癌 靶向治疗 耐药 |
| 英文关键词:gastric cancer targeted therapy drug resistance |
| 基金项目:国家自然科学基金项目（81670594）；兰州大学第二医院“萃英科技创新”计划项目（CY2017?鄄ZD01）；甘肃省科技重大专项（19ZD2WA001）；兰州市城关区科技计划项目（2019RCCX0034） |
|
| 摘要点击次数: 1133 |
| 全文下载次数: 416 |
| 中文摘要: |
| 摘 要：胃癌在我国的发病率远高于其他国家，长期以来，手术和化疗一直是胃癌患者的首选治疗方法。由于大多数患者在诊断时已经处于疾病中晚期，胃癌的预后一直不能令人满意。随着胃癌分子生物学的发展，靶向治疗作为一种新的治疗方法，成功地延长了胃癌患者的总生存期。继靶向药物抗HER2抗体曲妥珠单抗获得成功后，阻断不同关键途径的新药物相继出现。然而几乎所有患者在治疗过程中会出现一定程度耐药。全文就各国指南推荐的胃癌靶向治疗药物及耐药机制进行综述，为未来胃癌靶向治疗药物的研究提供参考。 |
| 英文摘要: |
| Abstract： The incidence of gastric cancer in China is much higher than that in other countries. For a long time， surgery and chemotherapy have been the preferred treatment methods for patients with gastric cancer. However， the majority of gastric cancer patients are diagnosed at advanced stages and the prognosis of gastric cancer has been unsatisfactory. With the advances in molecular biology of gastric cancer， targeted therapy has become a hotspot of clinical application， which has successfully extended the overall survival of advanced gastric cancer patients. Following the success of targeted drug trastuzumab—an anti-HER2 antibody， new drugs that block different key pathways are emerging rapidly； however， almost all patients develop drug resistance during treatment. This article reviews the progress of targeted therapy drug for gastric cancer recommended by various guidelines and the related mechanisms of drug resistance， to provide reference for targeted therapy of gastric cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |